Treprostinil benefits PAH patients with cardiovascular issues

PHA Canada
Feb 4, 2025
1 min read

Patients with pulmonary arterial hypertension (PAH) often also have cardiovascular issues such as diabetes or heart disease. A new analysis of data from two clinical trials indicated that treprostinil (Remodulin) in addition to existing treatment was safe and effective in preventing clinical worsening for these patients.

Read the CHEST journal article here

Recent Posts

Biomarkers identified for high-altitude PH

This study looked at which proteins and metabolic biomarkers might be associated with the development of high-altitude pulmonary hypertension (PH). Looking at data from China, from rat tissues, and fr

Smoking delays PAH diagnosis, but not CTEPH

Researchers looked at whether cigarette smoking affected the diagnosis and disease progression of patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension

Environmental triggers may contribute to heritable PAH

This study tried to identify new environmental triggers or genetic causes in heritable pulmonary arterial hypertension. They found several potential genes for further exploration, but they also found

Comments